SQZ vs. FNCH, ELOX, GMDAQ, WINT, ACORQ, SCNI, PKBO, IGNY, GNCA, and ALVO
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include Finch Therapeutics Group (FNCH), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Acorda Therapeutics (ACORQ), Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), Ignyte Acquisition (IGNY), Genocea Biosciences (GNCA), and Alvotech (ALVO). These companies are all part of the "biological products, except diagnostic" industry.
Finch Therapeutics Group (NASDAQ:FNCH) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Finch Therapeutics Group has a net margin of 0.00% compared to Finch Therapeutics Group's net margin of -369.96%. SQZ Biotechnologies' return on equity of -68.11% beat Finch Therapeutics Group's return on equity.
In the previous week, Finch Therapeutics Group had 2 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 2 mentions for Finch Therapeutics Group and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.96 beat Finch Therapeutics Group's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the media.
Finch Therapeutics Group and SQZ Biotechnologies both received 10 outperform votes by MarketBeat users. However, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
Finch Therapeutics Group has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Finch Therapeutics Group has higher earnings, but lower revenue than SQZ Biotechnologies. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Finch Therapeutics Group beats SQZ Biotechnologies on 8 of the 14 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
